Drugs / MB-CART2019.1
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07178431 | Apr 2026 → Aug 2030 expected | multiple sclerosis | Miltenyi Biomedicine GmbH | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07288879 | Dec 2025 → Jan 2027 expected | diffuse large B-cell lymphoma | Miltenyi Biomedicine GmbH | Recruiting | No outcome recorded |
| Phase 2 | NCT04844866 | Aug 2021 → Jan 2025 overdue | diffuse large B-cell lymphoma | Miltenyi Biomedicine GmbH | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06508775 | May 2024 → Dec 2040 expected | childhood acute lymphoblastic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, melanoma | Miltenyi Biomedicine GmbH | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB-CART2019.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07288879 ↗ |
| Known as | zamtocabtagene autoleucel | “DALY II Japan is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with...” NCT07288879 ↗ |
| Modality | Cell therapy | “MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells” NCT04844866 ↗ |
| Route | Intravenous | “Cell infusion will be administered intravenously” NCT07288879 ↗ |